BioSpace News Archive

Cytovia Therapeutics, Inc, an emerging biopharmaceutical company developing natural killer immunotherapies for cancer, announces that it has acquired worldwide rights from CytoImmune Therapeutics for its novel EGFR Dual-targeting CAR to be used for NK cell therapy.

Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, announced that its president and chief executive officer, Steven Lo, will present a company overview at the BTIG Biotechnology Conference 2020 on Tuesday, August 11, 2020 at 3:00 pm ET.

Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced presentations at two upcoming investor conferences in August. Karin Jooss, Ph.D., executive vice president of research and chief scientific officer, will present at the William Blair Biotech Focus Conference 2020 on Wednesday, August 5, 2020 at 2:25 p.m. ET.

-- Appointed David Meeker, M.D., as President and Chief Executive Officer – -- FDA granted rare pediatric disease designations for setmelanotide for the treatment of POMC and LEPR deficiency obesities -- -- Submitted MAA to EMA for setmelanotide in POMC and LEPR deficiency obesities -- -- Received FDA acceptance of NDA for setmelanotide for POMC and LEPR deficiency obesities for filing; assigned PDUFA goal date of November 27, 2020 – -- On track to announce topline data from pivotal

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced its participation in fireside chats at the following upcoming August investor conferences: BTIG Virtual Biotechnology Conference on Monday, August 10, 2020 at 1:00 p.m. ET. Wedbush PacGrow Healthcare Virtual Conference on Tue

Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the appointment of Ellen K. Forest as Chief Human Resources Officer. Ms. Forest brings 17 years of human resources experience to Yumanity including managing biopharmaceutical organizations through periods of growth. “Yumanity has made significant

Pfizer, in partnership with leading patient advocacy organizations and healthcare professionals, provides women and men living with metastatic breast cancer with a new tool to have informed conversations with their doctors about their treatment options

AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and prevention of COVID-19, announced today the publication of the paper, " An update on GM-CSF and its potential role in melanoma management ,” in the journal Melanoma Management. Robert O. Dillman , M.D., chief med

Announces distribution of nearly 12,000 specimen collection kits to clients and has current availability of approximately 18,000 kits for immediate distribution Expects Company-developed collection kits to be available later this quarter

VelosBio Inc . (“VelosBio”), a clinical-stage biopharmaceutical company committed to developing novel, first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), today announced the appointment of Dr. Enoch Kariuki as Chief Financial Officer. Dr. Kariuki will lead all finance-related and investor relations functions at the Company. Dr. Kariuki is a highly accomplished finance executi